Vaccine for RA one step closer


Results from a Phase I first in-human trial from Queensland shows that a single injection of autologous modified dendritic cells exposed to citrullinated peptides can suppress immune response in patients with RA. HLA risk genotype-positive RA patients who received the immunotherapy treatment Rheumavax had a reduced number of effector T cells and a decreased production ...


Already a member? Login to keep reading


OR
© 2017 the limbic